#### **PRACTICE GUIDELINE**

# 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary

A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines

Developed in Collaboration With the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons

#### Writing Committee Members\*

L. David Hillis, MD, FACC, *Chair*†
Peter K. Smith, MD, FACC, *Vice Chair\**†

Jeffrey L. Anderson, MD, FACC, FAHA\*‡
John A. Bittl, MD, FACC§
Charles R. Bridges, MD, ScD, FACC, FAHA\*†
John G. Byrne, MD, FACC†
Joaquin E. Cigarroa, MD, FACC†
Verdi J. DiSesa, MD, FACC†
Loren F. Hiratzka, MD, FACC, FAHA†
Adolph M. Hutter, JR, MD, MACC, FAHA†
Michael E. Jessen, MD, FACC\*†
Ellen C. Keeley, MD, MS†
Stephen J. Lahey, MD†
Richard A. Lange, MD, FACC, FAHA†§
Martin J. London, MD||

Michael J. Mack, MD, FACC\*¶
Manesh R. Patel, MD, FACC†
John D. Puskas, MD, FACC\*†
Joseph F. Sabik, MD, FACC\*#
Ola Selnes, PhD†
David M. Shahian, MD, FACC, FAHA\*\*
Jeffrey C. Trost, MD, FACC\*†
Michael D. Winniford, MD, FACC†

\*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information. †ACCF/AHA Representative. ‡ACCF/AHA Task Force on Practice Guidelines Liaison. §Joint Revascularization Section Author. ||Society of Cardiovascular Anesthesiologists Representative. ¶American Association for Thoracic Surgery Representative. #Society of Thoracic Surgeons Representative. \*\*ACCF/AHA Task Force on Performance Measures Liaison.

#### ACCF/AHA Task Force Members

Alice K. Jacobs, MD, FACC, FAHA, *Chair* Jeffrey L. Anderson, MD, FACC, FAHA, *Chair-Elect* 

Nancy Albert, PhD, CCNS, CCRN, FAHA Mark A. Creager, MD, FACC, FAHA Steven M. Ettinger, MD, FACC Robert A. Guyton, MD, FACC Jonathan L. Halperin, MD, FACC, FAHA Judith S. Hochman, MD, FACC, FAHA Frederick G. Kushner, MD, FACC, FAHA E. Magnus Ohman, MD, FACC William Stevenson, MD, FACC, FAHA Clyde W. Yancy, MD, FACC, FAHA

This document was approved by the American College of Cardiology Foundation Board of Trustees and American Heart Association Science Advisory and Coordinating Committee in July 2011, by the Society of Cardiovascular Anesthesiologists and Society of Thoracic Surgeons in August 2011, and by the American Association for Thoracic Surgery in September 2011.

The American College of Cardiology Foundation requests that this document be cited as follows: Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JC, Cigarroa JE, DiSesa VJ, Hiratzka LF, Hutter AM Jr., Jessen ME, Keeley EC, Lahey SJ, Lange RA, London MJ, Mack MJ, Patel MR, Puskas JD, Sabik JF, Selnes O, Shahian DM, Trost JC, Winniford MD. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;58:2584–614.

This article is copublished in Circulation, Anesthesia & Analgesia, and the Journal of Thoracic and Cardiovascular Surgery.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.cardiosource.org), and the American Heart Association (my.americanheart.org). For copies of this document, please contact the Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail reprints@elsevier.com.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please contact healthpermissions@elsevier.com.

Hillis et al.

Pre	ABLE	OF CONTENTS	
	eambl	<b>e</b>	.258.
1.	Intro	duction	.258
	1.1.	Methodology and Evidence Review	.258
		Organization of the Writing Committee	
		Document Review and Approval	
2		edural Considerations; Recommendations	
_			
	2.1.	Anesthetic Considerations	.258
	2.2.	Bypass Graft Conduit	.2589
	2.3.	Intraoperative Transesophageal Echocardiography	.2589
	2.4.	Preconditioning/Management of	
		Myocardial Ischemia	.2589
	2.5.	Clinical Subsets	.2589
		2.5.1. CABG in Patients With Acute	a
		Myocardial Infarction	
		2.5.2. Energency CABG After Failed PCI	259
		2.5.4. CABG in Association With Other	.237
		Cardiac Procedures	.259
	CAD	Revascularization: Recommendations	.2590
	3.1.	Heart Team Approach to	
		Revascularization Decisions	.259
	3.2.	Revascularization to Improve Survival	.259
		Revascularization to Improve Symptoms	
		Clinical Factors That May Influence the	
		Choice of Revascularization	
		3.4.1. Dual Antiplatelet Therapy Compliance and Stent Thrombosis	259
	3.5.	Hybrid Coronary Revascularization	
		perative Management: Recommendations	
_	Perio	perauve management: Recommendations	259.
	4.1.	Preoperative Antiplatelet Therapy	.2593
	4.2.		
		Postoperative Antiplatelet Therapy	.2593
		Postoperative Antiplatelet Therapy	
	4.3.		.259
	4.3. 4.4.	Management of Hyperlipidemia	.259 .259
	4.3. 4.4. 4.5.	Management of Hyperlipidemia Hormonal Manipulation	.259- .259- .259-
	4.3. 4.4. 4.5. 4.6.	Management of Hyperlipidemia  Hormonal Manipulation  Perioperative Beta Blockers  Angiotensin-Converting Enzyme Inhibitors	.2594 .2594 .2594
	4.3. 4.4. 4.5. 4.6.	Management of Hyperlipidemia Hormonal Manipulation Perioperative Beta Blockers Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers Smoking Cessation Emotional Dysfunction and	.259- .259- .259- .259-
	4.3. 4.4. 4.5. 4.6. 4.7. 4.8.	Management of Hyperlipidemia Hormonal Manipulation Perioperative Beta Blockers Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers Smoking Cessation Emotional Dysfunction and Psychosocial Considerations	.259- .259- .259- .259-
	4.3. 4.4. 4.5. 4.6. 4.7. 4.8.	Management of Hyperlipidemia Hormonal Manipulation Perioperative Beta Blockers Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers Smoking Cessation Emotional Dysfunction and Psychosocial Considerations Cardiac Rehabilitation	.259 <sup>4</sup> .259 <sup>4</sup> .259 <sup>4</sup> .259 <sup>4</sup> .259 <sup>5</sup>
	4.3. 4.4. 4.5. 4.6. 4.7. 4.8. 4.9.	Management of Hyperlipidemia Hormonal Manipulation Perioperative Beta Blockers Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers Smoking Cessation Emotional Dysfunction and Psychosocial Considerations Cardiac Rehabilitation Perioperative Monitoring	.259 <sup>4</sup> .259 <sup>4</sup> .259 <sup>4</sup> .259 <sup>4</sup> .259 <sup>5</sup> .259 <sup>5</sup>
	4.3. 4.4. 4.5. 4.6. 4.7. 4.8. 4.9.	Management of Hyperlipidemia Hormonal Manipulation Perioperative Beta Blockers Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers Smoking Cessation Emotional Dysfunction and Psychosocial Considerations Cardiac Rehabilitation Perioperative Monitoring 4.10.1. Electrocardiographic Monitoring	.2594 .2594 .2594 .2594 .2595 .2595 .2595
	4.3. 4.4. 4.5. 4.6. 4.7. 4.8. 4.9.	Management of Hyperlipidemia Hormonal Manipulation Perioperative Beta Blockers Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers Smoking Cessation Emotional Dysfunction and Psychosocial Considerations Cardiac Rehabilitation Perioperative Monitoring 4.10.1. Electrocardiographic Monitoring 4.10.2. Pulmonary Artery Catheterization	.2594 .2594 .2594 .2594 .2595 .2595 .2595 .2595 .2595
	4.3. 4.4. 4.5. 4.6. 4.7. 4.8. 4.9.	Management of Hyperlipidemia Hormonal Manipulation Perioperative Beta Blockers Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers Smoking Cessation Emotional Dysfunction and Psychosocial Considerations Cardiac Rehabilitation Perioperative Monitoring 4.10.1. Electrocardiographic Monitoring 4.10.2. Pulmonary Artery Catheterization 4.10.3. Central Nervous System Monitoring	.259 <sup>2</sup> .259 <sup>2</sup> .259 <sup>2</sup> .259 <sup>2</sup> .259 <sup>2</sup> .259 <sup>2</sup> .259 <sup>2</sup> .259 <sup>2</sup> .259 <sup>2</sup>
j.	4.3. 4.4. 4.5. 4.6. 4.7. 4.8. 4.9. 4.10.	Management of Hyperlipidemia Hormonal Manipulation Perioperative Beta Blockers Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers Smoking Cessation Emotional Dysfunction and Psychosocial Considerations Cardiac Rehabilitation Perioperative Monitoring 4.10.1. Electrocardiographic Monitoring 4.10.2. Pulmonary Artery Catheterization	.2594 .2594 .2594 .2594 .2595 .2595 .2595 .2595 .2595

	5.1.1. Use of Outcomes or Volume as		
	CABG Quality Measures		
5.2.	Use of Epiaortic Ultrasound Imaging		
	to Reduce Stroke Rates		
5.3.	The Role of Preoperative Carotid Artery Noninvasive Screening in CABG Patients		
5.4.	Mediastinitis/Perioperative Infection2596		
5.5.	Renal Dysfunction		
5.6.	Perioperative Myocardial Dysfunction25965.6.1. Transfusion2596		
5.7.	Perioperative Dysrhythmias		
5.8.	Perioperative Bleeding/Transfusion		
6. Speci	ific Patient Subsets: Recommendations		
6.1.	Anomalous Coronary Arteries		
6.2.	Patients With Chronic Obstructive Pulmonary Disease/Respiratory Insufficiency		
6.3.	Patients With End-Stage Renal Disease on Dialysis		
6.4.	<b>Patients With Concomitant Valvular Disease</b> 2597		
6.5.	Patients With Previous Cardiac Surgery 2597		
References			
	x 1. Author Relationships With Industry er Entities (Relevant)		
	x 2. Reviewer Relationships With Industry		
	er Entities (Relevant)		

#### **Preamble**

The medical profession should play a central role in evaluating the evidence related to drugs, devices, and procedures for the detection, management, and prevention of disease. When properly applied, expert analysis of available data on the benefits and risks of these therapies and procedures can improve the quality of care, optimize patient outcomes, and favorably affect costs by focusing resources on the most effective strategies. An organized and directed approach to a thorough review of evidence has resulted in the production of clinical practice guidelines that assist physicians in selecting the best management strategy for an individual patient. Moreover, clinical practice guidelines can provide a foundation for other applications, such as performance measures, appropriate use criteria, and both quality improvement and clinical decision support tools.

The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have jointly produced guidelines in the area of cardiovascular disease since 1980. The ACCF/AHA Task Force on Practice Guidelines (Task Force), charged with developing, updating, and revising practice guidelines for cardiovascular diseases and procedures, directs and oversees this effort. Writing committees are charged with regularly reviewing

### Download English Version:

## https://daneshyari.com/en/article/2947541

Download Persian Version:

https://daneshyari.com/article/2947541

<u>Daneshyari.com</u>